| Leukemia, Myelocytic, Acute
Rezlidhia vs Rydapt
Side-by-side clinical, coverage, and cost comparison for leukemia, myelocytic, acute.Deep comparison between: Rezlidhia vs Rydapt with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsRydapt has a higher rate of injection site reactions vs Rezlidhia based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Rydapt but not Rezlidhia, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Rezlidhia
Rydapt
At A Glance
Oral
Twice daily
IDH1 inhibitor
Oral
Twice daily
Multi-kinase inhibitor
Indications
- Leukemia, Myelocytic, Acute
- Leukemia, Myelocytic, Acute
- Aggressive Systemic Mastocytosis
- Systemic mastocytosis with associated clonal, hematologic non-mast-cell lineage disease
- Leukemia, Mast-Cell
Dosing
Leukemia, Myelocytic, Acute 150 mg orally twice daily until disease progression or unacceptable toxicity; take on an empty stomach at least 1 hour before or 2 hours after a meal.
Leukemia, Myelocytic, Acute 50 mg orally twice daily with food on Days 8 to 21 of each induction cycle with cytarabine and daunorubicin and on Days 8 to 21 of each consolidation cycle with high-dose cytarabine.
Aggressive Systemic Mastocytosis, Systemic mastocytosis with associated clonal, hematologic non-mast-cell lineage disease, Leukemia, Mast-Cell 100 mg orally twice daily with food; continue until disease progression or unacceptable toxicity.
Contraindications
—
- Hypersensitivity to midostaurin or any excipient, including reactions such as anaphylactic shock, dyspnea, flushing, chest pain, and angioedema
Adverse Reactions
Most common (>=20%) AST increased, ALT increased, potassium decreased, sodium decreased, alkaline phosphatase increased, nausea, creatinine increased, fatigue/malaise, arthralgia, constipation, lymphocytes increased, bilirubin increased, leukocytosis, uric acid increased, dyspnea, pyrexia, rash, lipase increased, mucositis, diarrhea, transaminitis
Serious Differentiation syndrome, transaminitis
Most common (>=20%) - AML Febrile neutropenia, nausea, mucositis, vomiting, headache, petechiae, musculoskeletal pain, epistaxis, device-related infection, hyperglycemia, ECG QT prolonged, upper respiratory tract infections
Most common (>=20%) - Systemic Mastocytosis Nausea, vomiting, diarrhea, edema, musculoskeletal pain, abdominal pain, fatigue, upper respiratory tract infection, constipation, pyrexia, headache, dyspnea
Serious Pulmonary toxicity, febrile neutropenia, sepsis, gastrointestinal hemorrhage, pneumonia, cardiac events
Postmarketing Interstitial lung disease, acute febrile neutrophilic dermatosis (Sweet syndrome)
Pharmacology
Olutasidenib is a small-molecule inhibitor of mutated isocitrate dehydrogenase-1 (IDH1); it inhibits mutant IDH1 proteins (R132H, R132C, and others), reducing 2-hydroxyglutarate (2-HG) levels in leukemia cells and promoting differentiation.
Midostaurin is a multi-kinase inhibitor that inhibits wild type and mutant FLT3, KIT (wild type and D816V), PDGFRalpha/beta, and members of the PKC serine/threonine kinase family, inducing apoptosis in leukemic cells expressing FLT3 mutations and inhibiting KIT signaling and histamine release in mast cells.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Rezlidhia
- Covered on 5 commercial plans
- PA (11/12) · Step Therapy (0/12) · Qty limit (11/12)
No coverage data available for Rydapt.
UnitedHealthcare
Rezlidhia
- Covered on 4 commercial plans
- PA (6/8) · Step Therapy (0/8) · Qty limit (2/8)
No coverage data available for Rydapt.
Humana
Rezlidhia
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (0/3) · Qty limit (2/3)
No coverage data available for Rydapt.
Coverage data sourced from MMIT. Updated monthly.
Savings
$15/fillfill
Rezlidhia CoPay AssistanceCommercial or private insurance
Medicare, Medicaid, VA, TRICARE
$25/momo
Novartis Oncology Universal Co-pay Program: RydaptCommercial or private insurance
Medicare, Medicaid, VA, TRICARE
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
RezlidhiaView full Rezlidhia profile
RydaptView full Rydapt profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.